Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients

Inclusion Criteria for prostate cancer patients:

* localised prostate cancer, histologically proven
* Absence of metastases (M0) : normal bone scintigraphy
* Absence of radiological lymph node invasion (N0).
* Clinical Stage : T ≥ T1c-T2a and \< T3b Or T1b or c with PSA ≤ 10 ng/ml . Or T1b or c with Gleason ≥ 6
* PSA \< 30 ng/ml.
* Signs and symptoms according to NCI/CTC v3.0 \< grade 2
* ECOG Performance status ≤ 1
* Absence of hip prothesis
* Absence de endopenian stent
* Patient aged \> 18 and \< 80
* Patient affiliated with social security
* Written informed consent, dated and signed

Exclusion Criteria for prostate cancer patients:

* Antecedents of invasive cancer (unless if treated more than 5 years ago without evolution) except basocellular carcinoma
* positive biopsy of seminal vesicle
* PSA ≥ 30 ng/ml for two successive dosages
* Previous pelvic irradiation
* Previous radical prostatectomy for cancer
* Patients with another systemic disease (cardiovascular, renal, hepatic, pulmonary embolism, etc.) non stabilised or generalised sclerodermitis.
* Patients known to be HIV seropositive (no specific test is necessary for defining eligibility)
* Known homozygote ATM (Ataxy telangiectasy) mutation
* Impossibility for a correct follow up (for social family or geographical reasons)
* Patients incapable of providing consent, protected majors, vulnerable persons
* Patients participating in other clinical trials

Inclusion Criteria for breast cancer patients:

* Breast Conservative surgery
* Non metastatic, M0
* negative surgical margins
* T1, T2; negative sentinel lymph node N0, N1 or N2.
* Signs and symptoms according to NCI/CTC v3.0 \< grade 2
* Patient aged over 18 years and less than 60 or more than 60 with an indication for boost irradiation.
* Patient affiliated with social security
* Written informed consent, dated and signed

Exclusion Criteria for breast cancer patients:

* Metastatic patients
* Bilateral breast cancer (concomitant or previous) except in situ
* T4 or N3 or treated by mastectomy
* Patients with chemotherapy or neoadjuvant hormonotherapy
* Patients with a previous other cancer within the last 5 years EXCEPT basocellular carcinoma of the skin or in situ cancer of the uterus.
* Patients with another systemic disease (cardiovascular, renal, hepatic, pulmonary embolism, etc.) non stabilised or generalised sclerodermia.
* Pregnant or breast feeding women
* Patients known to be HIV seropositive (no specific test is necessary for defining eligibility)
* Known homozygote ATM (Ataxy telangiectasy) mutation
* Impossibility for a correct follow up (for social family or geographical reasons)
* Patients incapable of providing consent, protected majors, vulnerable persons
* Patients participating in other clinical trials